| GTO ID | GTC3649 |
| Trial ID | NCT06112327 |
| Disease | Atherosclerotic Cardiovascular Disease | Heterozygous Familial Hypercholesterolemia |
| Therapy | Gene editing |
| Treatment | gene editing therapy |
| Recruitment status | Enrolling By Invitation |
| Title | Long-term Follow-up Study of Investigational Gene-editing Therapies in Participants With or at High Risk for Cardiovascular Disease |
| Year | 2023 |
| Country | New Zealand|United Kingdom |
| Company sponsor | Verve Therapeutics, Inc. |
| Other ID(s) | LTF-001 |
| Cohort 1 | |||||||
|
|||||||